Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study

PURPOSE: Data suggest that DNA damage by poly (ADP-ribose) polymerase inhibition and/or reduced vascular endothelial growth factor signaling by vascular endothelial growth factor receptor inhibition may complement antitumor activity of immune checkpoint blockade. We hypothesize the programmed death-...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Lee, Jung-Min, Cimino-Mathews, Ashley, Peer, Cody J., Zimmer, Alexandra, Lipkowitz, Stanley, Annunziata, Christina M., Cao, Liang, Harrell, Maria I., Swisher, Elizabeth M., Houston, Nicole, Botesteanu, Dana-Adriana, Taube, Janis M., Thompson, Elizabeth, Ogurtsova, Aleksandra, Xu, Haiying, Nguyen, Jeffers, Ho, Tony W., Figg, William D., Kohn, Elise C.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2017
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5493052/
https://ncbi.nlm.nih.gov/pubmed/28471727
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2016.72.1340
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados